Prognosys builds radiology and fluoroscopy solutions under the brand name PRORAD at its facility based out of Bengaluru
Molbio Diagnostics has acquired a 70 per cent stake in Bengaluru-based Prognosys Medical Systems, manufacturer of the Prorad range of Digital X-Ray units and C-arms and developer of a comprehensive digital health platform.
The acquisition further strengthens Molbio’s vision of taking health care to the people and adds one more significant weapon to its armoury to help India and the rest of the world, battle deadly communicable and non-communicable diseases.
Prognosys builds radiology and fluoroscopy solutions under the brand name PRORAD at its facility based out of Bengaluru that complies with national and international regulatory requirements such as CDSCO, BIS, AERB, EN ISO 13485, European CE and US FDA.
The recent introduction of the unique PRORAD Portable and Ultra-Portable digital x-ray units manufactured, for the first time in India, by Prognosys, can deliver high-quality chest images combined with Artificial Intelligence (AI) driven algorithms for automated interpreting and reporting at the point of care. The combination of PRORAD and Truenat system offers a game-changing solution for screening and confirming large populations for highly contagious and devastating diseases such as TB, covid and other chest anomalies.
The technology will be offered alongside Molbio’s patented Truenat technology, a point-of-care, portable, battery-operated Real-Time PCR platform that can screen over 40 diseases with a sample-to-result time of 60 minutes.
Molbio and Prognosys are already working together on mobile solutions for end-to-end screening and diagnosis of MTB and E-Clinics for delivering comprehensive health care to the last mile.
Speaking on the partnership, Sriram Natarajan, CEO, Founder, and Director, of Molbio Diagnostics, said, “Molbio is committed to bringing a range of cost-effective, high-quality point-of-care solutions. The majority acquisition of Prognosys Medical Systems is yet another step in this direction and helps us expand our “Universal Access” portfolio. Such solutions are going to alter the way we identify and treat communicable and non-communicable diseases that are currently difficult to eradicate. We are proud that the entire solution is being designed, developed, and manufactured in India for the world.”
Also commenting on the partnership, Dr Chandrasekhar Nair, CTO, and Director, of Molbio Diagnostics, said, “The ability to provide an entire end-to-end solution that can be carried to the point of care is a game changer. Molbio and Prognosys will further leverage their expertise and resources to develop rapid, accurate, and affordable solutions that combined with the digital healthcare platform can be used to realise the Hon.PM’s dream of “Ayushman Bharat” through “Atmanirbhar Bharat”.
Krishna Prasad, President, Prognosys said, “We are excited about this partnership with Molbio Diagnostics, a pioneer in the industry that develops pathbreaking technologies in molecular diagnostics and the IVD field. We are certain that with our combined capabilities to design and build world-class solutions in India, a true Make in India initiative, we will be able to significantly enhance the efforts of the government to eradicate deadly diseases like tuberculosis.”
